Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lushang Freda Pharmaceutical Co Days Payable Chart
Lushang Freda Pharmaceutical Co Days Payable Competitor Comparison
For the Real Estate - Development subindustry, Lushang Freda Pharmaceutical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lushang Freda Pharmaceutical Co Days Payable vs Real Estate Industry
For the Real Estate industry and Real Estate sector, Lushang Freda Pharmaceutical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Lushang Freda Pharmaceutical Co's Days Payable falls into.
Lushang Freda Pharmaceutical Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lushang Freda Pharmaceutical Co (SHSE:600223) has a Days Payable of 66.39 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lushang Freda Pharmaceutical Co and its competitors. This is 75% below median its historical median of 266.92. Over the past decade, Lushang Freda Pharmaceutical Co's Days Payable has ranged from 71.29 to 723.93. According to the industry distribution chart, Lushang Freda Pharmaceutical Co ranks #903 out of 1571 companies in the Real Estate industry, placing it in the top 57.5%.
Is Lushang Freda Pharmaceutical Co's Days Payable too high?
Lushang Freda Pharmaceutical Co's current Days Payable of 66.39 is 75% below median its 10-year median of 266.92. Over the past 10 years, this metric has ranged from a low of 71.29 to a high of 723.93. The Real Estate industry median Days Payable is 92.71. Lushang Freda Pharmaceutical Co's value of 66.39 is 28.4% below this industry median. Based on the distribution chart, Lushang Freda Pharmaceutical Co ranks #903 out of 1571 companies in the Real Estate industry, which is below the industry midpoint. Overall, Lushang Freda Pharmaceutical Co has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lushang Freda Pharmaceutical Co's Days Payable compare to competitors?
According to the Real Estate industry distribution chart, Lushang Freda Pharmaceutical Co ranks #903 out of 1571 companies for Days Payable. This places Lushang Freda Pharmaceutical Co in the lower half of its industry. The industry median Days Payable is 92.71. Lushang Freda Pharmaceutical Co's value of 66.39 is 28.4% below this benchmark. Historically, Lushang Freda Pharmaceutical Co's own Days Payable has ranged from 71.29 to 723.93 over the past decade. While the company's 10-year median is 266.92 vs. the industry median of 92.71, Lushang Freda Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Real Estate company?
The median Days Payable among Real Estate companies is 92.71, based on 1,571 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lushang Freda Pharmaceutical Co's current Days Payable of 66.39 is 28.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lushang Freda Pharmaceutical Co and its competitors. For the Real Estate industry, the median Days Payable is 92.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lushang Freda Pharmaceutical Co's current Days Payable is 66.39, which is 75% below median its own 10-year median of 266.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lushang Freda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co (SHSE:600223) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥6.56, compared to a current price of ¥5.51 — trading 16% below its estimated fair value. The current Days Payable is 66.39, which is 75% below median its 10-year median of 266.92 and 28.4% below the Real Estate industry median of 92.71. Lushang Freda Pharmaceutical Co's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Lushang Freda Pharmaceutical Co (SHSE:600223), the current Days Payable is 66.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lushang Freda Pharmaceutical Co (SHSE:600223) Overvalued in 2026?
Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥5.51 is trading 16% below its estimated GF Value™ of ¥6.56.
GuruFocus considers Lushang Freda Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600223:
Days Payable: 66.39 (75% below median its 10-year median of 266.92)
GF Value™: ¥6.56 vs. price of ¥5.51 (16% below fair value)
Industry Position: 28.4% below the Real Estate median (#903 of 1571)
No single metric tells the full story. See the SHSE:600223 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lushang Freda Pharmaceutical Co Ltd formerly Lushang Health Industry Development Co Ltd is a real estate developer in China. The company is engaged in the development of office buildings, infrastructure, apartments, and hotels.
68GF Score
Get the complete analysis for SHSE:600223
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600223 has been successfully added to your 
